Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies

(2015) Kensei Tobinai et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Dreyling et al.   ANNALS OF ONCOLOGY

Mantle cell lymphoma: evolving management strategies

(2014) Elias Campo et al.   BLOOD

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

(2013) M. Dreyling et al.   ANNALS OF ONCOLOGY

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2010) Ken Ohmachi et al.   CANCER SCIENCE

How I treat mantle cell lymphoma

(2009) M. Ghielmini et al.   BLOOD